News related to Rituxan (Rituximab) and/or conditions it is approved for
Rituximab Plus Bendamustine vs Standard Therapy for CLL
Source: Medscape Hematology-Oncology Headlines [2016.05.27]
For patients with chronic lymphocytic leukemia (CLL), the combination of rituximab plus bendamustine was less effective than standard therapy, but it was also less toxic.
Medscape Medical News
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2016.04.22]
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.
Source: MedicineNet Biological Therapy Specialty [2015.04.01]
Title: Non-Hodgkin's Lymphoma
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 4/1/2015 12:00:00 AM